Pfizer Inc. (PFE)
| Previous Close | 49.92 |
| Open | 49.87 |
| Bid | 50.56 x 1000 |
| Ask | 50.57 x 900 |
| Day's Range | 49.91 - 50.83 |
| 52 Week Range | 38.48 - 61.71 |
| Volume | |
| Avg. Volume | 28,420,171 |
| Market Cap | 284.376B |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | 14.47 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.60 (2.93%) |
| Ex-Dividend Date | Jan 27, 2022 |
| 1y Target Est | N/A |
- Business Wire
Pfizer to Acquire Biohaven Pharmaceuticals
NEW YORK & NEW HAVEN, CONN., May 10, 2022--Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.
- GlobeNewswire
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
BASEL, Switzerland, and NEW YORK, May 06, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis. The FDA requires extended time to review additional information the Ag
- Business Wire
Pfizer Reports First-Quarter 2022 Results
NEW YORK, May 03, 2022--Pfizer Inc. (NYSE: PFE) reported strong financial results for first-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer reaffirmed its previous 2022 revenue guidance, including its guidance for Comirnaty(1), the Pfizer-BioNTech SE (BioNTech) COVID-19 vaccine, and for Paxlovid, its oral COVID-19 treatment, despite unfavorable impacts from foreign exchange.
